Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ZUCLOPENTHIXOL Cause Neuroleptic malignant syndrome? 125 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 125 reports of Neuroleptic malignant syndrome have been filed in association with ZUCLOPENTHIXOL. This represents 5.2% of all adverse event reports for ZUCLOPENTHIXOL.

125
Reports of Neuroleptic malignant syndrome with ZUCLOPENTHIXOL
5.2%
of all ZUCLOPENTHIXOL reports
0
Deaths
98
Hospitalizations

How Dangerous Is Neuroleptic malignant syndrome From ZUCLOPENTHIXOL?

Of the 125 reports, 98 (78.4%) required hospitalization, and 57 (45.6%) were considered life-threatening.

Is Neuroleptic malignant syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ZUCLOPENTHIXOL. However, 125 reports have been filed with the FAERS database.

What Other Side Effects Does ZUCLOPENTHIXOL Cause?

Drug ineffective (660) Dyskinesia (414) Schizophrenia (409) Dystonia (404) Sedation (403) Sexual dysfunction (394) Suicide attempt (389) Blood glucose increased (379) Anosognosia (374) Blood prolactin abnormal (374)

What Other Drugs Cause Neuroleptic malignant syndrome?

QUETIAPINE (1,756) OLANZAPINE (1,748) RISPERIDONE (1,258) HALOPERIDOL (1,244) ARIPIPRAZOLE (1,138) CLOZAPINE (899) LITHIUM (506) LORAZEPAM (437) PALIPERIDONE (355) VALPROIC ACID (352)

Which ZUCLOPENTHIXOL Alternatives Have Lower Neuroleptic malignant syndrome Risk?

ZUCLOPENTHIXOL vs ZUCLOPENTHIXOL DECANOATE ZUCLOPENTHIXOL vs ZURANOLONE ZUCLOPENTHIXOL vs ZYPREXA ZUCLOPENTHIXOL vs ZYTIGA ZUCLOPENTHIXOL vs ZYVOX

Related Pages

ZUCLOPENTHIXOL Full Profile All Neuroleptic malignant syndrome Reports All Drugs Causing Neuroleptic malignant syndrome ZUCLOPENTHIXOL Demographics